- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03311945
Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM (RALAM-RollOver)
July 30, 2018 updated by: David Garcia Cinca
Phase 3b, Single Arm, Single Site Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM Clinical Trial (NCT02284035)
Phase 3b, single arm, single site simplification study of HIV-1 infected patients with virological suppression under the combination of Lamivudine (150 mg BID) plus Raltegravir (400 mg BID) switching to Lamivudine (300 mg QD) plus Raltegravir (1200 mg QD): Roll-over study of the RALAM clinical trial (NCT02284035)
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
49
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Esteban Martinez, MD
- Phone Number: +34.227.54.00
- Email: ESTEBANM@clinic.cat
Study Locations
-
-
-
Barcelona, Spain, 08036
- Recruiting
- Hospital Clinic i Provincial de Barcelona
-
Contact:
- Esteban Martinez, MD
- Phone Number: +34.227.54.00
- Email: ESTEBANM@clinic.cat
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients in the switch arm who have completed the 24-week follow-up of RALAM (NCT02284035) study and remain virologically suppressed (viral load <50 copies/mL) on dual therapy with lamivudine plus Raltegravir
- Patients who have signed informed consent to participate in the study.
Exclusion Criteria:
- Pregnancy, lactation, or planned pregnancy during the study period
- Any disease or history of disease which, in opinion of the investigator, might confound the results of the study or pose additional risk to patient treatment
- Hepatitis B co-infection
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Raltegravir + Lamivudine
Lamivudine (300 mg QD) plusRaltegravir (1200 mg QD)
|
Raltegravir (1200 mg QD)
Lamivudine (300 mg QD)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with herapeutic failure
Time Frame: 48 weeks
|
Proportion of patients that at least present one of the following events: virological failure, change in antirretroviral treatment for any reason, consent withdrawal, loss to follow-up or death
|
48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with herapeutic failure
Time Frame: 24 weeks
|
Proportion of patients that at least present one of the following events: virological failure, change in antirretroviral treatment for any reason, consent withdrawal, loss to follow-up or death
|
24 weeks
|
Proportion of patients with viral load below ultrasensitive HIV-1 RNA detection limit (limit of detection 1 copy/mL)
Time Frame: 48 weeks
|
48 weeks
|
|
Change from baseline in peripheral mononuclear blood cells HIV-1 reservoir
Time Frame: 48 weeks
|
48 weeks
|
|
Changes from baseline in cholesterol total
Time Frame: 24 weeks
|
24 weeks
|
|
Changes from baseline in cholesterol LDL
Time Frame: 24 weeks
|
24 weeks
|
|
Changes from baseline in cholesterol HDL
Time Frame: 24 weeks
|
24 weeks
|
|
Changes from baseline in triglycerides
Time Frame: 24 weeks
|
24 weeks
|
|
Changes from baseline in insulin resistance (HOMA-IR)
Time Frame: 24 weeks
|
24 weeks
|
|
Changes from baseline in cholesterol total
Time Frame: 48 weeks
|
48 weeks
|
|
Changes from baseline in cholesterol LDL
Time Frame: 48 weeks
|
48 weeks
|
|
Changes from baseline in triglycerides
Time Frame: 48 weeks
|
48 weeks
|
|
Changes from baseline in insulin resistance (HOMA-IR)
Time Frame: 48 weeks
|
48 weeks
|
|
Change from baseline in lumbar and femoral bone mineral density
Time Frame: 48 weeks
|
48 weeks
|
|
Change from baseline in plasma 25-OH vitamin D levels
Time Frame: 48 weeks
|
48 weeks
|
|
Change from baseline in urine beta-2-microglobulin
Time Frame: 48 weeks
|
48 weeks
|
|
Change from baseline in estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology CollaborationI)
Time Frame: 48 weeks
|
48 weeks
|
|
Change from baseline in urine protein/creatinine ratio
Time Frame: 48 weeks
|
48 weeks
|
|
Changes from baseline in biomarkers of inflammation IL-6
Time Frame: 48 weeks
|
48 weeks
|
|
Changes from baseline in biomarker of mononuclear activation SD-163
Time Frame: 48 weeks
|
48 weeks
|
|
Changes from baseline in biomarker of mononuclear activation SD-14
Time Frame: 48 weeks
|
48 weeks
|
|
Changes from baseline in biomarker of inflammation high sensitivity C-reactive protein
Time Frame: 48 weeks
|
48 weeks
|
|
Changes from baseline in sleep quality (Pittsburgh Sleep Quality Index) at
Time Frame: 48 weeks
|
48 weeks
|
|
Change from baseline in EQ-5D-5L
Time Frame: 48 weeks
|
48 weeks
|
|
Incidence of adverse events
Time Frame: 48 weeks
|
48 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 3, 2018
Primary Completion (ANTICIPATED)
March 30, 2020
Study Completion (ANTICIPATED)
March 30, 2020
Study Registration Dates
First Submitted
September 29, 2017
First Submitted That Met QC Criteria
October 11, 2017
First Posted (ACTUAL)
October 17, 2017
Study Record Updates
Last Update Posted (ACTUAL)
July 31, 2018
Last Update Submitted That Met QC Criteria
July 30, 2018
Last Verified
July 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Disease Attributes
- HIV Infections
- Infections
- Communicable Diseases
- HIV Seropositivity
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- HIV Integrase Inhibitors
- Integrase Inhibitors
- Raltegravir Potassium
- Lamivudine
Other Study ID Numbers
- 2017-000986-60
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Raltegravir
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV InfectionsUnited States, Puerto Rico, South Africa, Argentina, Brazil, Botswana
-
Massachusetts General HospitalMerck Sharp & Dohme LLCCompletedHIV | Neurotoxicity | HIV-associated Neurocognitive DisorderUnited States
-
ViiV HealthcareCompletedInfection, Human Immunodeficiency VirusUnited States
-
Merck Sharp & Dohme LLCCompleted
-
ANRS, Emerging Infectious DiseasesCompletedHIV-1 Infection | PREGNANCYFrance
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompletedHIV Infections | Infection, Human Immunodeficiency VirusUnited States, France, Netherlands, Spain, Taiwan, Australia, Belgium, Russian Federation, Canada, United Kingdom, Mexico, Italy, South Africa, Romania, Argentina, Hungary, Poland, Chile, Greece, Brazil
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompletedInfection, Human Immunodeficiency Virus IGermany, Spain, France, Australia, United States, Canada, United Kingdom, Italy, Russian Federation
-
IrsiCaixaCompleted